HTG Molecular Diagnostics (NASDAQ:HTGM): H.C. Wainwright Reconfirms “Buy” Rating Today, Has a Target of $6.0/Share

September 17, 2017 - By Maria Brooks

 HTG Molecular Diagnostics (NASDAQ:HTGM): H.C. Wainwright Reconfirms

HTG Molecular Diagnostics (NASDAQ:HTGM) Rating Reaffirmed

H.C. Wainwright now has a $6.0 price target on shares of HTG Molecular Diagnostics (NASDAQ:HTGM). The price target would suggest a potential upside of 237.08 % from the previous close of HTG Molecular Diagnostics (NASDAQ:HTGM). This rating was released in analysts note on Tuesday morning.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Ratings Coverage

Among 3 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics has $12.0 highest and $5 lowest target. $7’s average target is 293.26% above currents $1.78 stock price. HTG Molecular Diagnostics had 7 analyst reports since August 24, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Monday, August 24 with “Buy”. The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has “Buy” rating given on Monday, August 22 by Rodman & Renshaw. H.C. Wainwright maintained HTG Molecular Diagnostics Inc (NASDAQ:HTGM) rating on Wednesday, August 9. H.C. Wainwright has “Buy” rating and $600 target. The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has “Buy” rating given on Tuesday, November 24 by Canaccord Genuity. H.C. Wainwright maintained HTG Molecular Diagnostics Inc (NASDAQ:HTGM) on Friday, July 28 with “Buy” rating. H.C. Wainwright maintained HTG Molecular Diagnostics Inc (NASDAQ:HTGM) on Tuesday, September 12 with “Buy” rating. The company was maintained on Thursday, June 29 by H.C. Wainwright.

The stock decreased 5.32% or $0.1 on September 15, reaching $1.78. About 268,296 shares traded. HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has risen 34.13% since September 17, 2016 and is uptrending. It has outperformed by 17.43% the S&P500.

HTG Molecular Diagnostics, Inc. is a commercial-stage firm that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The company has market cap of $20.38 million. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. It currently has negative earnings. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples.

More notable recent HTG Molecular Diagnostics Inc (NASDAQ:HTGM) news were published by: Globenewswire.com which released: “HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU” on March 22, 2017, also Seekingalpha.com with their article: “HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q2 2017 Results – Earnings …” published on August 09, 2017, Globenewswire.com published: “HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual …” on September 06, 2017. More interesting news about HTG Molecular Diagnostics Inc (NASDAQ:HTGM) were released by: Globenewswire.com and their article: “HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate …” published on April 24, 2017 as well as Globenewswire.com‘s news article titled: “HTG Molecular Diagnostics Announces Second Companion Diagnostic Development …” with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.